Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Current and future outlook on disease modification and defining low disease activity in systemic sclerosis.

Nagaraja V, Cerinic MM, Furst DE, Kuwana M, Allanore Y, Denton CP, Raghu G, Mclaughlin V, Rao PS, Seibold JR, Pauling JD, Whitfield ML, Khanna D.

Arthritis Rheumatol. 2020 Mar 5. doi: 10.1002/art.41246. [Epub ahead of print] Review.

PMID:
32134199
2.

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.

Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM.

J Heart Lung Transplant. 2020 Apr;39(4):300-309. doi: 10.1016/j.healun.2019.12.013. Epub 2020 Jan 21.

3.

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.

McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, Li M, Sitbon O, Tapson V, Frost A.

Chest. 2019 Nov 16. pii: S0012-3692(19)34214-X. doi: 10.1016/j.chest.2019.10.043. [Epub ahead of print]

4.

Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.

McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM; AMBITION Study Group.

J Heart Lung Transplant. 2019 Dec;38(12):1286-1295. doi: 10.1016/j.healun.2019.09.010. Epub 2019 Sep 17.

5.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE.

Respir Res. 2019 Sep 12;20(1):208. doi: 10.1186/s12931-019-1180-1.

6.

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.

Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano Subías P, Sood N, Keogh A, D'Souza G, Rubin L.

Eur Respir J. 2019 Oct 10;54(4). pii: 1901030. doi: 10.1183/13993003.01030-2019. Print 2019 Oct.

PMID:
31391223
7.

Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.

Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, McLaughlin V, Khanna D.

Eur Respir J. 2019 Aug 22;54(2). pii: 1900586. doi: 10.1183/13993003.00586-2019. Print 2019 Aug.

PMID:
31196948
8.

Barriers to physical activity in patients with pulmonary hypertension.

Cascino TM, McLaughlin VV, Richardson CR, Behbahani-Nejad N, Moles VM, Visovatti SH, Jackson EA.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019847895. doi: 10.1177/2045894019847895.

9.

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF.

Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

10.

An insider view on the World Symposium on Pulmonary Hypertension.

Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Lancet Respir Med. 2019 Jun;7(6):484-485. doi: 10.1016/S2213-2600(19)30111-0. Epub 2019 Apr 4. No abstract available.

PMID:
30956061
11.

Physical activity and quality of life in patients with pulmonary hypertension.

Cascino TM, McLaughlin VV, Richardson CR, Behbahani-Nejad N, Moles VM, Visovatti SH, Jackson EA.

Eur Respir J. 2019 Jun 20;53(6). pii: 1900028. doi: 10.1183/13993003.00028-2019. Print 2019 Jun. No abstract available.

PMID:
30880287
12.

EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.

Benza R, Corris P, Ghofrani A, Kanwar MK, McLaughlin VV, Raina A, Simonneau G.

Pulm Circ. 2019 Feb 26:2045894019837849. doi: 10.1177/2045894019837849. [Epub ahead of print] No abstract available.

13.

Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.

Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, Flaherty K, McLaughlin V, Khanna D.

Arthritis Rheumatol. 2019 Aug;71(8):1339-1349. doi: 10.1002/art.40862. Epub 2019 Jun 18.

PMID:
30762947
14.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

15.

An overview of the 6th World Symposium on Pulmonary Hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir J. 2019 Jan 24;53(1). pii: 1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. No abstract available.

16.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

17.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

18.

Pulmonary Hypertension in Women.

Franco V, Ryan JJ, McLaughlin VV.

Heart Fail Clin. 2019 Jan;15(1):137-145. doi: 10.1016/j.hfc.2018.08.013. Epub 2018 Oct 24. Review.

PMID:
30449376
19.

Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D.

Semin Arthritis Rheum. 2019 Jun;48(6):1059-1067. doi: 10.1016/j.semarthrit.2018.10.010. Epub 2018 Oct 14.

20.

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.

Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V.

J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12.

21.

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.

Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB.

Chest. 2018 Oct;154(4):848-861. doi: 10.1016/j.chest.2018.04.027. Epub 2018 Apr 26.

22.

Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management.

Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC.

Arrhythm Electrophysiol Rev. 2018 Mar;7(1):43-48. doi: 10.15420/aer.2018.3.2.

23.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

24.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

25.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

26.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

27.

Pulmonary arterial hypertension: tailoring treatment to risk in the current era.

Gaine S, McLaughlin V.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170095. doi: 10.1183/16000617.0095-2017. Print 2017 Dec 31. Review.

28.

Update on pulmonary arterial hypertension research: proceedings from a meeting of experts.

McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L.

Curr Med Res Opin. 2018 Feb;34(2):263-273. doi: 10.1080/03007995.2017.1404974. Epub 2017 Dec 22.

PMID:
29132217
29.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
30.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
31.

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.

Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM.

Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug.

32.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

33.

Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension.

Bhave NM, Visovatti SH, Kulick B, Kolias TJ, McLaughlin VV.

Int J Cardiovasc Imaging. 2017 Jun;33(6):847-855. doi: 10.1007/s10554-017-1081-7. Epub 2017 Feb 6.

34.

Usefulness of Echocardiography/Doppler to Reliably Predict Elevated Left Ventricular End-Diastolic Pressure in Patients With Pulmonary Hypertension.

Cameron DM, McLaughlin VV, Rubenfire M, Visovatti S, Bach DS.

Am J Cardiol. 2017 Mar 1;119(5):790-794. doi: 10.1016/j.amjcard.2016.11.016. Epub 2016 Dec 2.

PMID:
28040189
35.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

36.

Future perspectives in pulmonary arterial hypertension.

Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N.

Eur Respir Rev. 2016 Dec;25(142):381-389. doi: 10.1183/16000617.0084-2016. Review.

37.

Safety of regadenoson stress testing in patients with pulmonary hypertension.

Moles VM, Cascino T, Saleh A, Mikhova K, Lazarus JJ, Ghannam M, Yun HJ, Konerman M, Weinberg RL, Ficaro EP, Corbett JR, McLaughlin VV, Murthy VL.

J Nucl Cardiol. 2018 Jun;25(3):820-827. doi: 10.1007/s12350-016-0734-6. Epub 2016 Nov 28.

PMID:
27896702
38.

Beast of Pulmonary Arterial Hypertension Burden.

Mathai SC, McLaughlin VV.

JAMA Cardiol. 2016 Dec 1;1(9):1030-1031. doi: 10.1001/jamacardio.2016.3829. No abstract available.

PMID:
27851836
39.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
40.

Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel.

Sista AK, Goldhaber SZ, Vedantham S, Kline JA, Kuo WT, Kahn SR, Kabrhel C, McLaughlin VV, White SB, Kim NH, Gray M, Simon MA, Benenati JF, Misra S, Sterling KM, Kee ST, Konstantinides SV, Jaff MR, Kearon C.

J Vasc Interv Radiol. 2016 Jun;27(6):787-94. doi: 10.1016/j.jvir.2016.03.035. Epub 2016 Jun 3. No abstract available.

PMID:
27287967
41.

Treatment of pulmonary hypertension.

Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N.

Lancet Respir Med. 2016 Apr;4(4):323-36. doi: 10.1016/S2213-2600(15)00542-1. Epub 2016 Mar 12. Review.

PMID:
26975811
42.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

43.

Improving patient outcomes in pulmonary hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir Rev. 2015 Dec;24(138):550-1. doi: 10.1183/16000617.0064-2015. No abstract available.

44.

Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!

Khanna D, McLaughlin V.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1032-3. doi: 10.1164/rccm.201509-1881ED. No abstract available.

PMID:
26517415
45.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

46.

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM.

Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.

47.

Management of pulmonary arterial hypertension.

McLaughlin VV, Shah SJ, Souza R, Humbert M.

J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540. Review.

48.

[Treatment goals of pulmonary hypertension].

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:95-105. Turkish.

49.

[Updated treatment algorithm of pulmonary arterial hypertension].

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:78-94. Turkish.

50.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D.

Arthritis Res Ther. 2014 Dec 10;16(6):493. doi: 10.1186/s13075-014-0493-1.

Supplemental Content

Loading ...
Support Center